OCS stock news · Oculis Holding AG
Get alerts for OCS
Follow Oculis Holding AG (OCS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for OCSGuggenheim still thinks Oculis Holding is a good buy but has cut its price target to $40.
NeutralGuggenheim kept its Buy rating on Oculis but cut its target from $45 to $40, an 11.1% drop. This mixed opinion reports no change in Oculis's business.
Oculis says it will share its financial results on November 5, 2026.
NeutralOculis set November 5, 2026, as the date for its quarterly results. The notice reports no new company results, so it does not change the outlook.
Oculis shares new results from its Phase 2 ACUITY study on Privosegtor.
Good for OCSOculis reported Phase 2 results showing improved visual function and maintained retinal structure. This supports its treatment research, but does not prove the treatment will work broadly.
Oculis says it is making headway on buying back its own shares.
NeutralOculis reported recent purchases of its own shares under an existing plan. With no purchase amount or share count, this update does not change the company's outlook.